HC Wainwright Reaffirms “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

HC Wainwright restated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report issued on Friday morning, Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a sell rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Lexicon Pharmaceuticals currently has a consensus rating of Hold and an average price target of $7.50.

Lexicon Pharmaceuticals Trading Up 3.9 %

LXRX stock opened at $1.60 on Friday. The company has a market capitalization of $393.98 million, a PE ratio of -1.93 and a beta of 1.33. Lexicon Pharmaceuticals has a one year low of $0.92 and a one year high of $3.73. The company’s 50 day moving average price is $1.77 and its two-hundred day moving average price is $1.85. The company has a debt-to-equity ratio of 0.41, a quick ratio of 11.49 and a current ratio of 11.51.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. The firm had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $2.74 million. During the same quarter last year, the business earned ($0.22) earnings per share. As a group, analysts predict that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its holdings in Lexicon Pharmaceuticals by 82.6% in the first quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 26,859 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Lexicon Pharmaceuticals by 7.0% in the first quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock valued at $15,363,000 after acquiring an additional 420,854 shares in the last quarter. Virtu Financial LLC bought a new stake in Lexicon Pharmaceuticals in the first quarter valued at $105,000. Hennion & Walsh Asset Management Inc. bought a new stake in Lexicon Pharmaceuticals in the second quarter valued at $912,000. Finally, BVF Inc. IL boosted its holdings in Lexicon Pharmaceuticals by 22.2% in the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after acquiring an additional 4,440,300 shares in the last quarter. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.